Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Liabilities and Shareholders Equity (2021 - 2025)

Historic Liabilities and Shareholders Equity for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $3.3 billion.

  • Rxo's Liabilities and Shareholders Equity fell 401.29% to $3.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $13.0 billion, marking a year-over-year increase of 2462.08%. This contributed to the annual value of $3.3 billion for FY2025, which is 401.29% down from last year.
  • Per Rxo's latest filing, its Liabilities and Shareholders Equity stood at $3.3 billion for Q4 2025, which was down 401.29% from $3.2 billion recorded in Q3 2025.
  • Rxo's 5-year Liabilities and Shareholders Equity high stood at $3.4 billion for Q4 2024, and its period low was $1.8 billion during Q1 2024.
  • Over the past 5 years, Rxo's median Liabilities and Shareholders Equity value was $2.1 billion (recorded in 2021), while the average stood at $2.5 billion.
  • In the last 5 years, Rxo's Liabilities and Shareholders Equity tumbled by 1300.85% in 2023 and then skyrocketed by 8706.85% in 2024.
  • Quarter analysis of 5 years shows Rxo's Liabilities and Shareholders Equity stood at $2.1 billion in 2021, then dropped by 1.79% to $2.0 billion in 2022, then dropped by 10.14% to $1.8 billion in 2023, then skyrocketed by 87.07% to $3.4 billion in 2024, then decreased by 4.01% to $3.3 billion in 2025.
  • Its last three reported values are $3.3 billion in Q4 2025, $3.2 billion for Q3 2025, and $3.2 billion during Q2 2025.